Rexahn Pharmaceuticals (RNN) 0.75 $RNN
Rexahn Pharmaceuticals to Present at the BioPharm America(TM) 2014 in Boston, Massachusetts, USA
Business Wire - Tue Sep 16, 8:00AM CDT
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that Vikas Sharma, PhD, Director of Business Development, will present at the BioPharm America(TM) 2014 conference in Boston, Massachusetts, USA. The presentation will be on Tuesday, September 23rd at 3:00 PM EDT. The conference is being held September 22-24, 2014, at Boston Marriott Copley Place, Boston, Massachusetts, USA.
Rexahn Pharmaceuticals (RNN) Jumps: Stock Rises 9.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 8:39AM CDT
Rexahn Pharmaceuticals, Inc. (RNN) was a big mover last session, as its shares rose almost 10% on the day.
Rexahn Pharmaceuticals to Present at the 16th Annual Rodman & Renshaw Global Investment Conference on September 9, 2014
Business Wire - Thu Sep 04, 8:00AM CDT
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that Peter D. Suzdak, PhD, the Company's Chief Executive Officer, will present at the 16th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co, LLC. The presentation will be on Tuesday, September 9th at 12:05 PM EDT. The presentation will be webcast live. To access the webcast, please visit http://wsw.com/webcast/rrshq24/rnn. The conference is being held September 8-10, 2014, at The Palace Hotel in New York City.
Hot Stock: Rexahn Pharmaceuticals, Shares Gain 8.9% (RNN)
Comtex SmarTrend(R) - Wed Sep 03, 10:07AM CDT
Rexahn Pharmaceuticals (AMEX:RNN) is one of today's best performing penny stocks, up 8.9% to $0.76 on 2.8x average daily volume. Rexahn Pharmaceuticals has traded 2.1 million shares thus far today, vs. average volume of 735,000 shares per day. The stock has outperformed the Dow (8.9% to the Dow's 0.4%) and outperformed the S&P 500 (8.9% to the S&P's 0.2%) during today's trading.
Rexahn Receives a Notice of Allowance from the U.S. Patent and Trademark Office for a Novel Targeted Cancer Drug Delivery Platform
Business Wire - Wed Sep 03, 8:00AM CDT
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced it has received a notice of allowance from the United States Patent and Trademark Office for a new delivery technology titled, "Polymeric Systems for the Delivery of Anticancer Drugs". The patent covers CPMA, a new polymer drug delivery platform technology developed by Rexahn.
Market Movers - Biotech Stocks -- Progenics Pharma, Rexahn Pharma, ImmunoGen, Hemispherx Biopharma, and Incyte
PR Newswire - Thu Aug 21, 8:20AM CDT
On Wednesday, August 20, 2014, the NASDAQ Composite ended at 4,526.48, down 0.02%, the Dow Jones Industrial Average finished the day 0.35% higher at 16,979.13, and the S&P 500 closed at 1,986.51, up 0.25%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 726.51, up 0.01%, and the index has advanced 2.23% in the last one month. Investor-Edge has initiated coverage on the following equities: Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN), ImmunoGen Inc. (NASDAQ: IMGN), Hemispherx Biopharma Inc. (NYSE MKT: HEB), and Incyte Corporation (NASDAQ: INCY). Free research on these five companies can be accessed at:
Rexahn Pharmaceuticals Reports Second Quarter 2014 Financial Results and Pipeline Update
Business Wire - Thu Aug 14, 8:00AM CDT
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, is providing an overview of its three clinical development programs and financial results for the quarter ended June 30, 2014.
Rexahn Pharmaceuticals Provides Update on Phase I Supinoxin Trial in Cancer Patients with Solid Tumors
Business Wire - Fri Jul 18, 8:00AM CDT
Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced an update in its Phase I multi-center dose-escalation study to evaluate the safety, tolerability, dose-limiting toxicities and maximum tolerated dose (MTD) of Supinoxin(TM) (RX-5902) in cancer patients with solid tumors.
Stock to Watch: Rexahn Pharmaceuticals Down 5.2% (RNN)
Comtex SmarTrend(R) - Tue Jul 15, 10:38AM CDT
Rexahn Pharmaceuticals (AMEX:RNN) is one of today's worst performing penny stocks, down 5.2% to $0.76 on 1.1x average daily volume. Thus far today, Rexahn Pharmaceuticals has traded 1.4 million shares, vs. average volume of 1.3 million shares per day. The stock has underperformed the Dow (-5.1% to the Dow's -0.0%) and underperformed the S&P 500 (-5.1% to the S&P's -0.2%) during today's trading.
What Falling Estimates & Price Mean for Rexahn Pharmaceuticals (RNN) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 16, 7:45AM CDT
Rexahn Pharmaceuticals one such stock considered to drop as it has witnessed a significant price decline and has also seen negative earnings.
Stock to Watch: Rexahn Pharmaceuticals Up 7.7% (RNN)
Comtex SmarTrend(R) - Thu Jun 12, 10:41AM CDT
Rexahn Pharmaceuticals (AMEX:RNN) is one of today's best performing low-priced stocks, up 7.7% to $1.01 on 1.1x average daily volume. Thus far today, Rexahn Pharmaceuticals has traded 2.7 million shares, vs. average volume of 2.6 million shares per day. The stock has outperformed the Dow (8.3% to the Dow's -0.3%) and outperformed the S&P 500 (8.3% to the S&P's -0.3%) during today's trading.
Rexahn Pharmaceuticals to Present Data on RX-3117 and RX-21101 at the 2014 American Association for Clinical Research Annual Meeting
Business Wire - Wed Apr 02, 8:00AM CDT
--RX-21101, a nano-polymer targeted form of docetaxel, demonstrates increased efficacy and reduced toxicity
Active Equities Updates -- Research on Valero Energy, UTi Worldwide, SLM Corp., and Rexahn Pharma
PR Newswire - Tue Apr 01, 8:00AM CDT
The trading session on Monday, March 31, 2014 ended on a positive note as the Dow Jones Industrial Average finished at 16,457.66, up 0.82% and the NASDAQ Composite closed at 4,198.99, up 1.04%. The S&P 500 finished the session 0.79% higher at 1,872.34. The gains were broad based as nine out of ten sectors finished higher. During the session, gains in the Health Care, Materials, and Utilities sectors positively impacted the broader market. Investor-Edge looks at some of the equities which attracted the most attention and traded the most shares during the session. These include Valero Energy Corp. (NYSE: VLO), UTi Worldwide Inc. (NASDAQ: UTIW), SLM Corp. (NASDAQ: SLM) and Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN). Free technical research on VLO, UTIW, SLM and RNN can be downloaded upon signing up at:
Rexahn Pharmaceuticals Reports Fourth Quarter and Full-Year 2013 Financial Results and Recent Highlights
Business Wire - Mon Mar 24, 7:00AM CDT
--Archexin(R) Phase IIa clinical trial initiated in metastatic renal cell carcinoma
3 Stocks Under $10 Making Big Moves
at The Street - Wed Mar 19, 5:00AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Rexahn Pharmaceuticals to Present at the 2nd Annual Sachs Cancer Bio Partnering & Investment Forum in New York
Business Wire - Mon Mar 17, 7:00AM CDT
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that Vikas Sharma, Ph.D., the Company's Director, Business Development, will present at the 2nd Annual Sachs Cancer Bio Partnering & Investment Forum in New York on Wednesday, March 19, 2014. Dr. Sharma will also serve on an expert panel titled "Strategies for small molecules and biologicals drug development." The conference will take place at New York Academy of Sciences, located at 250 Greenwich St, New York, NY.
This Week in Biotech: NW Bio Soars While Geron Goes Geronimo
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 15, 2:15PM CDT
With the SPDR S&P Biotech Index up 59% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Phase I Data on Rexahn's Supinoxin - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 4:30PM CDT
Initial data from phase I study on Rexahn's Supinoxin showed that the drug was well tolerated in cancer patients with solid tumors.
Why Rexahn Pharmaceuticals Inc. Jumped Higher
Sean Williams, The Motley Fool - Motley Fool - Tue Mar 11, 1:58PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Rexahn Pharmaceuticals , a clinical-stage...
Rexahn Pharmaceuticals Up 11.1%, Shares Break Through Resistance (RNN)
Comtex SmarTrend(R) - Tue Mar 11, 11:41AM CDT
Rexahn Pharmaceuticals (AMEX:RNN) is one of today's best performing low-priced stocks, up 11.1% to $1.38 on 1.0x average daily volume. Thus far today, Rexahn Pharmaceuticals has traded 11.0 million shares, vs. average volume of 10.6 million shares per day. The stock has outperformed the Dow (10.7% to the Dow's -0.3%) and outperformed the S&P 500 (10.7% to the S&P's -0.3%) during today's trading.
Rexahn Pharmaceuticals to Present at the BioPharm America(TM) 2014 in Boston, Massachusetts, USA
Business Wire - Tue Sep 16, 8:00AM CDT
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that Vikas Sharma, PhD, Director of Business Development, will present at the BioPharm America(TM) 2014 conference in Boston, Massachusetts, USA. The presentation will be on Tuesday, September 23rd at 3:00 PM EDT. The conference is being held September 22-24, 2014, at Boston Marriott Copley Place, Boston, Massachusetts, USA.
Rexahn Pharmaceuticals (RNN) Jumps: Stock Rises 9.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 8:39AM CDT
Rexahn Pharmaceuticals, Inc. (RNN) was a big mover last session, as its shares rose almost 10% on the day.
Rexahn Pharmaceuticals to Present at the 16th Annual Rodman & Renshaw Global Investment Conference on September 9, 2014
Business Wire - Thu Sep 04, 8:00AM CDT
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that Peter D. Suzdak, PhD, the Company's Chief Executive Officer, will present at the 16th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co, LLC. The presentation will be on Tuesday, September 9th at 12:05 PM EDT. The presentation will be webcast live. To access the webcast, please visit http://wsw.com/webcast/rrshq24/rnn. The conference is being held September 8-10, 2014, at The Palace Hotel in New York City.
Hot Stock: Rexahn Pharmaceuticals, Shares Gain 8.9% (RNN)
Comtex SmarTrend(R) - Wed Sep 03, 10:07AM CDT
Rexahn Pharmaceuticals (AMEX:RNN) is one of today's best performing penny stocks, up 8.9% to $0.76 on 2.8x average daily volume. Rexahn Pharmaceuticals has traded 2.1 million shares thus far today, vs. average volume of 735,000 shares per day. The stock has outperformed the Dow (8.9% to the Dow's 0.4%) and outperformed the S&P 500 (8.9% to the S&P's 0.2%) during today's trading.
Rexahn Receives a Notice of Allowance from the U.S. Patent and Trademark Office for a Novel Targeted Cancer Drug Delivery Platform
Business Wire - Wed Sep 03, 8:00AM CDT
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced it has received a notice of allowance from the United States Patent and Trademark Office for a new delivery technology titled, "Polymeric Systems for the Delivery of Anticancer Drugs". The patent covers CPMA, a new polymer drug delivery platform technology developed by Rexahn.
Market Movers - Biotech Stocks -- Progenics Pharma, Rexahn Pharma, ImmunoGen, Hemispherx Biopharma, and Incyte
PR Newswire - Thu Aug 21, 8:20AM CDT
On Wednesday, August 20, 2014, the NASDAQ Composite ended at 4,526.48, down 0.02%, the Dow Jones Industrial Average finished the day 0.35% higher at 16,979.13, and the S&P 500 closed at 1,986.51, up 0.25%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 726.51, up 0.01%, and the index has advanced 2.23% in the last one month. Investor-Edge has initiated coverage on the following equities: Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN), ImmunoGen Inc. (NASDAQ: IMGN), Hemispherx Biopharma Inc. (NYSE MKT: HEB), and Incyte Corporation (NASDAQ: INCY). Free research on these five companies can be accessed at:
Rexahn Pharmaceuticals Reports Second Quarter 2014 Financial Results and Pipeline Update
Business Wire - Thu Aug 14, 8:00AM CDT
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, is providing an overview of its three clinical development programs and financial results for the quarter ended June 30, 2014.
Rexahn Pharmaceuticals Provides Update on Phase I Supinoxin Trial in Cancer Patients with Solid Tumors
Business Wire - Fri Jul 18, 8:00AM CDT
Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced an update in its Phase I multi-center dose-escalation study to evaluate the safety, tolerability, dose-limiting toxicities and maximum tolerated dose (MTD) of Supinoxin(TM) (RX-5902) in cancer patients with solid tumors.
Stock to Watch: Rexahn Pharmaceuticals Down 5.2% (RNN)
Comtex SmarTrend(R) - Tue Jul 15, 10:38AM CDT
Rexahn Pharmaceuticals (AMEX:RNN) is one of today's worst performing penny stocks, down 5.2% to $0.76 on 1.1x average daily volume. Thus far today, Rexahn Pharmaceuticals has traded 1.4 million shares, vs. average volume of 1.3 million shares per day. The stock has underperformed the Dow (-5.1% to the Dow's -0.0%) and underperformed the S&P 500 (-5.1% to the S&P's -0.2%) during today's trading.
What Falling Estimates & Price Mean for Rexahn Pharmaceuticals (RNN) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 16, 7:45AM CDT
Rexahn Pharmaceuticals one such stock considered to drop as it has witnessed a significant price decline and has also seen negative earnings.
Stock to Watch: Rexahn Pharmaceuticals Up 7.7% (RNN)
Comtex SmarTrend(R) - Thu Jun 12, 10:41AM CDT
Rexahn Pharmaceuticals (AMEX:RNN) is one of today's best performing low-priced stocks, up 7.7% to $1.01 on 1.1x average daily volume. Thus far today, Rexahn Pharmaceuticals has traded 2.7 million shares, vs. average volume of 2.6 million shares per day. The stock has outperformed the Dow (8.3% to the Dow's -0.3%) and outperformed the S&P 500 (8.3% to the S&P's -0.3%) during today's trading.
Rexahn Pharmaceuticals to Present Data on RX-3117 and RX-21101 at the 2014 American Association for Clinical Research Annual Meeting
Business Wire - Wed Apr 02, 8:00AM CDT
--RX-21101, a nano-polymer targeted form of docetaxel, demonstrates increased efficacy and reduced toxicity
Active Equities Updates -- Research on Valero Energy, UTi Worldwide, SLM Corp., and Rexahn Pharma
PR Newswire - Tue Apr 01, 8:00AM CDT
The trading session on Monday, March 31, 2014 ended on a positive note as the Dow Jones Industrial Average finished at 16,457.66, up 0.82% and the NASDAQ Composite closed at 4,198.99, up 1.04%. The S&P 500 finished the session 0.79% higher at 1,872.34. The gains were broad based as nine out of ten sectors finished higher. During the session, gains in the Health Care, Materials, and Utilities sectors positively impacted the broader market. Investor-Edge looks at some of the equities which attracted the most attention and traded the most shares during the session. These include Valero Energy Corp. (NYSE: VLO), UTi Worldwide Inc. (NASDAQ: UTIW), SLM Corp. (NASDAQ: SLM) and Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN). Free technical research on VLO, UTIW, SLM and RNN can be downloaded upon signing up at:
Rexahn Pharmaceuticals Reports Fourth Quarter and Full-Year 2013 Financial Results and Recent Highlights
Business Wire - Mon Mar 24, 7:00AM CDT
--Archexin(R) Phase IIa clinical trial initiated in metastatic renal cell carcinoma
3 Stocks Under $10 Making Big Moves
at The Street - Wed Mar 19, 5:00AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Rexahn Pharmaceuticals to Present at the 2nd Annual Sachs Cancer Bio Partnering & Investment Forum in New York
Business Wire - Mon Mar 17, 7:00AM CDT
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that Vikas Sharma, Ph.D., the Company's Director, Business Development, will present at the 2nd Annual Sachs Cancer Bio Partnering & Investment Forum in New York on Wednesday, March 19, 2014. Dr. Sharma will also serve on an expert panel titled "Strategies for small molecules and biologicals drug development." The conference will take place at New York Academy of Sciences, located at 250 Greenwich St, New York, NY.
This Week in Biotech: NW Bio Soars While Geron Goes Geronimo
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 15, 2:15PM CDT
With the SPDR S&P Biotech Index up 59% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Phase I Data on Rexahn's Supinoxin - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 4:30PM CDT
Initial data from phase I study on Rexahn's Supinoxin showed that the drug was well tolerated in cancer patients with solid tumors.
Why Rexahn Pharmaceuticals Inc. Jumped Higher
Sean Williams, The Motley Fool - Motley Fool - Tue Mar 11, 1:58PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Rexahn Pharmaceuticals , a clinical-stage...
Rexahn Pharmaceuticals Up 11.1%, Shares Break Through Resistance (RNN)
Comtex SmarTrend(R) - Tue Mar 11, 11:41AM CDT
Rexahn Pharmaceuticals (AMEX:RNN) is one of today's best performing low-priced stocks, up 11.1% to $1.38 on 1.0x average daily volume. Thus far today, Rexahn Pharmaceuticals has traded 11.0 million shares, vs. average volume of 10.6 million shares per day. The stock has outperformed the Dow (10.7% to the Dow's -0.3%) and outperformed the S&P 500 (10.7% to the S&P's -0.3%) during today's trading.
